Josamycin

Josamycin

Catalog Number:
M001341915TOK
Mfr. No.:
TOK-J001
Price:
$209
  • Size:
    Quantity:
    Add to Cart:
      • Overview
        • Josamycin is a macrolide antibiotic that inhibits protein synthesis. It has anti-cancer properties, as it is able to overcome P-glycoprotein-dependent drug resistance in cancerous tumors.

          Please contact us at for specific academic pricing.

          Background

          Josamycin inhibits peptide elongation on the ribosome by binding close to the peptidyltransferase center and blocking the peptide exit tunnel in the large ribosomal subunit. Synthesis of full-length proteins is completely shut down by Josamycin.

      • Properties
        • CAS Number
          16846-24-5
          Molecular Formula
          C42H69NO15
          Molecular Weight
          827.99
          Appearance
          White to light yellow powder
          Solubility
          Slightly soluble in ethanol, methanol and chloroform.
          Other Properties
          Source: Streptomyces kitasatoensis and Streptomyces narbonensis var. josamyceticus.
          Purity Level: ≥95%
          Storage
          2-8°C (protect from light and moisture)

          * For research use only

      • Applications
        • Application Description
          Spectrum: Gram-positive bacteria

          Eukaryotic Cell Culture Applications: Josamycin was evaluated in cell culture with peritoneal cells and splenic cells from BALB/c mice. Phagocytic activity of C. albicans and cytokine production (IL12 and IL-18) by peritoneal cells and IL-4 production by splenic cells was evaluated, and results indicated that Josamycin acts as an immunosuppressive agent (Ortega et al, 2004).

          Cancer Applications: Josamycin was found to increase the accumulation of vinblastine and cyclosporine A in a dose-dependent manner in anticancer drug-resistant cells (P388/ADR). Since it inhibits the binding of vinblastine and cyclosporine A to P-glycoprotein, it may be used to overcome anticancer drug resistance. In fact, combination chemotherapy with macrolide antibiotics like Josamycin may overcome P-glycoprotein-dependent drug-resistant tumors (Wang et al, 2000).

    Note: If you don't receive our verification email, do the following:

    Copyright © Amerigo Scientific. All rights reserved.